Type 1 Diabetes Market Size is USD 37.67 Billion in 2025

The global type 1 diabetes market size was valued at USD 34.91 billion in 2024, is projected to reach approximately USD 74.67 billion by 2034. Growing adoption of advanced insulin therapies and innovative diabetes management devices is expected to drive a steady CAGR of 7.9%.

Type 1 Diabetes Market Statical Scope

Why is the Type 1 Diabetes Market Growing?

The type 1 diabetes market is growing at a significant rate, driven by the rising prevalence of type 1 diabetes, which demands early diagnosis. Type 1 diabetes (T1D) is a chronic autoimmune condition in which the immune system attacks and destroys insulin-producing cells in the pancreas. These diseases require lifelong management with insulin therapies and glucose monitoring, creating a significant demand for healthcare consumables. The National Health Interview Survey conducted from 2019-2022 reported that 2 in every 1000 youths and 5 in every adults in the United States report having type 1 diabetes, which is consistent with the data from the Centers for Disease Control (CDC) from 2021. This is creating a huge demand for healthcare settings to adopt healthcare solutions.

What Factors Are Proving Obstacles for Growth in the Type 1 Diabetes Market?

The healthcare consumables market is growing rapidly, with advanced therapies and devices contributing to this growth. However, limited access to these facilities in rural areas is creating a barrier to manufacturers expanding their businesses faster. Additionally, these areas have lower awareness rates, leading to fewer diagnoses among children and youths, which certainly decreases supply and demand.

The growing digitalization in the healthcare sector is creating several business opportunities through mobile apps, wearable devices, and cloud-based monitoring, which help provide updates to patients with these conditions. The rise of stem cell therapy, immunotherapy, beta-cell regeneration, and more, which help address the root cause of the disease. Healthcare organizations are investing in clinical trials and research to develop advanced healthcare solutions in the coming years.

What are the Future Prospects of the Type 1 Diabetes Market?

The future of the type 1 diabetes market is expected to gain popularity as countries like India, China, and Southeast Asia are witnessing increasing patient volumes, which are constantly driving investments in the healthcare sector. The rising population in these urbanized areas is continually creating opportunities for companies to invest in healthcare to treat type 1 diabetes. Moreover, governments are also spreading awareness through campaigns to promote early disease diagnosis. The business in the country is expected to grow as the number of cost-effective analogs and monitoring devices increases.

What Is the Impact of Artificial Intelligence on the Type 1 Diabetes Market?

The automation enabled by machine learning ML and artificial intelligence AI is improving overall analysis of pancreatic systems, which can be used to optimize insulin doses. Early predictions about these technologies are also expected to help professionals and patients take precautionary measures. Additionally, the type 1 diabetes market is expected to grow as R&D efforts focus on drug discovery and device development.

Type 1 Diabetes Market Share, By Region, 2024 (%)

• North America – Holds 40% of the market, supported by high insulin usage, advanced diabetes technologies, and strong reimbursement systems. Dominates due to early adoption of pumps, CGMs, and digital care platforms.
• Europe – Represents 30% of the market, driven by robust healthcare systems and high prevalence of Type 1 diabetes. Gaining momentum with strong uptake of hybrid closed-loop technologies.
• Asia Pacific – Accounts for 20% of the market, reflecting rising diagnosis rates and expanding healthcare access. Gaining momentum as awareness, affordability, and adoption of modern insulin delivery methods increase.
• LAMEA – Holds 5% of the market, with growing diabetes incidence but limited access to advanced therapies. Not dominating due to cost constraints and uneven healthcare infrastructure.

Type 1 Diabetes Market Share, By Insulin Analog, 2024 (%)

• Rapid-Acting Insulin – Represents 45% of the market, widely used for rapid blood glucose control during meals. Slightly declines toward 2034 as long-acting regimens and automated insulin delivery systems reduce reliance on rapid corrections.
• Short-Acting Insulin – Holds 20% of the market, used in traditional basal–bolus therapy and clinical settings. Marginally declines by 2034 due to continued replacement by faster, more efficient rapid-acting and long-acting analogs.
• Long-Acting Insulin – Accounts for 35% of the market, providing steady basal coverage. Gains share through 2034 as demand grows for simplified regimens and compatibility with automated insulin pumps and AI-driven dosing systems.

Type 1 Diabetes Market Share, By Devices, 2024 (%)

• Insulin Pump – Represents 35% of the market, enabling continuous insulin infusion and integration with CGMs. Gains a few percentage points by 2034 as advanced pump–CGM ecosystems and closed-loop technologies become mainstream.
• Insulin Pen – Holds 30% of the market, offering convenience and ease of dosing. Remains stable as pens continue to serve large patient segments that prefer simple, non-device-dependent solutions.
• Blood Glucose Meter – Accounts for 25% of the market, used for manual blood glucose checks. Declines slightly by 2034 as CGMs and integrated pump platforms gain adoption.
• Others – Comprise 10% of the market, including patch devices and emerging digital tools. Gradually expand but remain a smaller segment due to lower adoption compared to established devices.

Type 1 Diabetes Market Share, By End-User, 2024 (%)

• Hospital – Represents 55% of the market, driven by inpatient diabetes management and acute care needs. Does not dominate future growth as more care shifts to outpatient and home-based models.
• Research Institutes – Holds 15% of the market, supporting drug development and clinical trials. Not dominating due to narrower application scope but remains essential for innovation.
• Home Care – Accounts for 30% of the market, driven by self-management tools and remote monitoring. Grows modestly to around 35% by 2034 as digital health, telemedicine, and home-based diabetes management rise.

Type 1 Diabetes Market Companies

• Eli Lilly
• Pfizer
• Abbott Laboratories
• DiaVasc, Inc.
• Biodel, Inc.
• Sanofi
• Merck
• Astellas Pharma
• Mannkind Corporation
  

Type 1 Diabetes Market Segmentation

By Insulin Analog

• Rapid-Acting Insulin
• Short-Acting Insulin
• Long-Acting Insulin

By Devices

• Insulin Pump
• Insulin Pen
• Blood Glucose Meter
• Others
  

By End-User

• Hospital
• Research Institutes
• Home Care

By Region

• North America
• Europe
• Asia Pacific
• LAMEA